Eye infections treatment sales will expand through 2036, with antibiotics holding 42.0% of the drug class segment in 2026, driven by high adoption across primary application categories. The market was valued at USD 8.16 billion in 2025 and is expected to be worth USD 13.52 billion by 2036.